US FDA’s Search For Class-Wide Vaccine Blood-Clot Effect Makes Scientific Sense, But Raises Questions
Executive Summary
Several adenovirus vaccine developers say the products cannot be compared, potentially complicating the US FDA and CDC’s decision on ending the recommended pause in the use of Janssen’s vaccine.
You may also be interested in...
J&J Vaccine: Some CDC Advisors Question Warning’s Strength As Clot Reports Grow, Female Use Drops
Some ACIP members argued woman older than 50 should also be singled out in warning for Johnson & Johnson’s COIVD-19 vaccine and said that people need to be more clearly told they can get alternative vaccines that don’t have this risk.
With J&J’s COVID Vaccine Pause Now Lifted, The Question Is How Well The System Worked
Number of deaths and ICU admissions that may have been prevented without the pause is ‘striking,’ CDC advisory committee member says; ACIP votes to reaffirm use of J&J’s vaccine in persons 18 and older based on positive risk-benefit analysis and reports of only nine additional cases of TTS.
With New Rare Blood Clot Warning, J&J COVID-19 Vaccine Rollout Resumes In EU
Similarities to AstraZeneca blood clots are clear, but more research needed before any ‘class effect’ conclusions can be drawn.